A Blueprint to Control the SARS-CoV-2 Pandemic
- 1 May 2021
- journal article
- editorial
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 96 (5) , 1128-1131
Abstract
No abstract availableFunding Information
- Mayo Clinic (109593, AI110173, AI120698)
- National Institutes of Health (109593, AI110173, AI120698)
- National Institute of Allergy and Infectious Diseases (109593, AI110173, AI120698)
This publication has 13 references indexed in Scilit:
- Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care WorkersNew England Journal of Medicine, 2021
- Immunological memory to SARS-CoV-2 assessed for up to 8 months after infectionScience, 2021
- SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19New England Journal of Medicine, 2021
- Dose-response Relation Deduced for Coronaviruses From Coronavirus Disease 2019, Severe Acute Respiratory Syndrome, and Middle East Respiratory Syndrome: Meta-analysis Results and its Application for Infection Risk Assessment of Aerosol TransmissionClinical Infectious Diseases, 2020
- The assessment of transmission efficiency and latent infection period in asymptomatic carriers of SARS-CoV-2 infectionInternational Journal of Infectious Diseases, 2020
- Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysisThe Lancet, 2020
- Viral dynamics in mild and severe cases of COVID-19The Lancet Infectious Diseases, 2020
- Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wardsEuropean Journal of Clinical Microbiology & Infectious Diseases, 2020
- Successful treatment of HIV eliminates sexual transmissionThe Lancet, 2019
- Receptor-Independent Infection of Murine Coronavirus: Analysis by SpinoculationJournal of Virology, 2006